|
|
Blood, 15 September 2004, Vol. 104, No. 6, pp. 1825-1832.
Prepublished online as a Blood First Edition Paper on May 25, 2004; DOI 10.1182/blood-2003-12-4218.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion–mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase
Ralf Schmidmaier,
Philipp Baumann,
Meral Simsek,
Farshid Dayyani,
Bertold Emmerich, and
Gerold Meinhardt
From the Laboratory for Molecular Haematology and Oncology of the Department of Haematology and Oncology, Medizinische Klinik Innenstadt, Klinikum der Universität München, Munich, Germany.
Primary drug resistance is a major problem in multiple myeloma, an incurable disease of the bone marrow. Cell adhesion-mediated drug resistance (CAM-DR) causes strong primary resistance. By coculturing multiple myeloma cells with bone marrow stromal cells (BMSCs), we observed a CAM-DR of about 50% to melphalan, treosulfan, doxorubicin, dexamethasone, and bortezomib, which was not reversed by secreted soluble factors. Targeting the adhesion molecules lymphocyte function–associated antigen 1 (LFA-1) and very late antigen 4 (VLA-4) by monoclonal antibodies or by the LFA-1 inhibitor LFA703 reduced CAM-DR significantly. Only statins such as simvastatin and lovastatin, however, were able to completely restore chemosensitivity. All these effects were not mediated by deadhesion or reduced secretion of interleukin 6. Targeting geranylgeranyl transferase (GGTase) and Rho kinase by specific inhibitors (GGTI-298 and Y-27632), but not inhibition of farnesyl transferase (FTase) by FTI-277, showed similar reduction of CAM-DR. Addition of geranylgeranyl pyrophosphate (GG-PP), but not of farnesyl pyrophosphate (F-PP), was able to inhibit simvastatin-induced CAM-DR reversal. Our data suggest that the 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA)/GG-PP/Rho/Rho-kinase pathway mediates CAM-DR and that targeting this pathway may improve the efficacy of antimyeloma therapies by reduction of CAM-DR.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Reducing cholesterol and overcoming drug resistance
- Steven Grant
Blood 2004 104: 1598-1599.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
Q. Chen, W. Xie, D. J. Kuhn, P. M. Voorhees, A. Lopez-Girona, D. Mendy, L. G. Corral, V. P. Krenitsky, W. Xu, L. Moutouh-de Parseval, et al.
Targeting the p27 E3 ligase SCFSkp2 results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy
Blood,
May 1, 2008;
111(9):
4690 - 4699.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Hatch, Y. Gu, F. Y. Xu, J. Cizeau, S. Neumann, J.-S. Park, S. Loewen, and M. R.A. Mowat
StARD13(Dlc-2) RhoGap Mediates Ceramide Activation of Phosphatidylglycerolphosphate Synthase and Drug Response in Chinese Hamster Ovary Cells
Mol. Biol. Cell,
March 1, 2008;
19(3):
1083 - 1092.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-H. Lee, Y. S. Cho, and Y.-M. Han
Simvastatin Suppresses Self-Renewal of Mouse Embryonic Stem Cells by Inhibiting RhoA Geranylgeranylation
Stem Cells,
July 1, 2007;
25(7):
1654 - 1663.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kobune, H. Chiba, J. Kato, K. Kato, K. Nakamura, Y. Kawano, K. Takada, R. Takimoto, T. Takayama, H. Hamada, et al.
Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism
Mol. Cancer Ther.,
June 1, 2007;
6(6):
1774 - 1784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. W.-L. Wong, J. W. Clendening, A. Martirosyan, P. C. Boutros, C. Bros, F. Khosravi, I. Jurisica, A. K. Stewart, P. L. Bergsagel, and L. Z. Penn
Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma
Mol. Cancer Ther.,
June 1, 2007;
6(6):
1886 - 1897.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Dai, P. Khanna, S. Chen, X.-Y. Pei, P. Dent, and S. Grant
Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation
Blood,
May 15, 2007;
109(10):
4415 - 4423.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Sekimoto, S. Ozaki, T. Ohshima, H. Shibata, T. Hashimoto, M. Abe, N. Kimura, K. Hattori, S. Kawai, Y. Kinoshita, et al.
A Single-Chain Fv Diabody against Human Leukocyte Antigen-A Molecules Specifically Induces Myeloma Cell Death in the Bone Marrow Environment
Cancer Res.,
February 1, 2007;
67(3):
1184 - 1192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chatterjee, S. Jain, T. Stuhmer, M. Andrulis, U. Ungethum, R.-J. Kuban, H. Lorentz, K. Bommert, M. Topp, D. Kramer, et al.
STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90{alpha} and {beta} in multiple myeloma cells, which critically contribute to tumor-cell survival
Blood,
January 15, 2007;
109(2):
720 - 728.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. C. Li, M. J. Park, S.-K. Ye, C.-W. Kim, and Y.-N. Kim
Elevated Levels of Cholesterol-Rich Lipid Rafts in Cancer Cells Are Correlated with Apoptosis Sensitivity Induced by Cholesterol-Depleting Agents
Am. J. Pathol.,
April 1, 2006;
168(4):
1107 - 1118.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kucia, R. Reca, K. Miekus, J. Wanzeck, W. Wojakowski, A. Janowska-Wieczorek, J. Ratajczak, and M. Z. Ratajczak
Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF-1-CXCR4 Axis
Stem Cells,
August 1, 2005;
23(7):
879 - 894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. W.C.J. van de Donk, H. M. Lokhorst, E. H.J. Nijhuis, M. M.J. Kamphuis, and A. C. Bloem
Geranylgeranylated Proteins are Involved in the Regulation of Myeloma Cell Growth
Clin. Cancer Res.,
January 15, 2005;
11(2):
429 - 439.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
